Exciting progress in targeted therapy innovation for unresectable stage III EGFR-mutated NSCLC: the phase III LAURA study.

Cancer Commun (Lond)

Department of Medical Oncology, The Second Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou, Zhejiang, P. R. China.

Published: October 2024

Download full-text PDF

Source
http://dx.doi.org/10.1002/cac2.12611DOI Listing

Publication Analysis

Top Keywords

exciting progress
4
progress targeted
4
targeted therapy
4
therapy innovation
4
innovation unresectable
4
unresectable stage
4
stage iii
4
iii egfr-mutated
4
egfr-mutated nsclc
4
nsclc phase
4

Similar Publications

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!